This randomized controlled trial published in JAMA Network Open tested a single psilocybin dose against an active placebo (niacin) in 35 participants with recurrent major depression, not limited to treatment-resistant cases. As an RCT with modest sample size, it offers higher internal validity than observational designs but carries risks of underpowering and the acknowledged blinding failure, where nearly all participants guessed their assignment due to psilocybin's unmistakable effects. Benefits emerged by day 8 and persisted over three months on self-reported measures, with over half achieving remission criteria versus one in placebo, though between-group gaps narrowed by six months amid natural symptom fluctuation and new antidepressant starts. The original coverage underplays how this aligns with prior peer-reviewed work, such as the 2021 Davis et al. RCT in JAMA (n=24, treatment-resistant focus) showing similar rapid onset, and the larger 2022 Goodwin et al. phase 2 trial in NEJM (n=233) confirming dose-dependent durability up to 12 weeks. What was missed is the mechanistic tie to 5-HT2A receptor agonism driving cortical neuroplasticity, per preclinical rodent models and human fMRI studies from Imperial College, potentially explaining months-long effects beyond expectation alone. Conflicts of interest in the field often involve industry funding for psychedelic sponsors, though this trial emphasized independent psychological support protocols. Overall, while promising for broader depression phenotypes, scaling requires better active placebos or dose-blinding innovations to isolate biological from contextual factors.